Recent blog posts
AstraZeneca JMC Reports on RXFP1 Agonist AZD5462
Hot Spotlight
5 min read
AstraZeneca JMC Reports on RXFP1 Agonist AZD5462
27 March 2024
Recently, AstraZeneca reported in detail the discovery process of the RXFP1 agonist AZD5462, currently in Phase II clinical trials, in two consecutive articles published in the top-tier journal JMC (Journal of Medicinal Chemistry).
Read →
Bristol Myers Squibb Invests $1.4 Billion in Layout for Schizophrenia Treatment Candidate Drugs
Hot Spotlight
8 min read
Bristol Myers Squibb Invests $1.4 Billion in Layout for Schizophrenia Treatment Candidate Drugs
27 March 2024
On March 18th, Bristol Myers Squibb (BMS) finalized its acquisition of Karuna Therapeutics, enhancing its neuroscience investments. Karuna has stopped NASDAQ trading and is now fully owned by BMS.
Read →
Sumitomo Pharma Renews Collaborative Development Agreement with Otsuka Pharmaceutical for Multiple Psychiatric Disorder Treatments
Hot Spotlight
8 min read
Sumitomo Pharma Renews Collaborative Development Agreement with Otsuka Pharmaceutical for Multiple Psychiatric Disorder Treatments
27 March 2024
Sumitomo Dainippon Pharma and its U.S. subsidiary SMPA announced an updated agreement on March 15th with Otsuka Pharmaceutical for the joint development of four psychiatric and neurological compounds, including ulotaront and others, amending their original September 30, 2021, partnership.
Read →
AstraZeneca's Strategic Layout for Targeting PTH1R in the Treatment of Hypoparathyroidism
Hot Spotlight
9 min read
AstraZeneca's Strategic Layout for Targeting PTH1R in the Treatment of Hypoparathyroidism
26 March 2024
On March 14, AstraZeneca plans to buy Amolyt Pharma, a biotech firm specializing in rare endocrine disorders, enhancing its Alexion unit with the phase III drug, eneboparatide, for hypoparathyroidism treatment.
Read →
Aprocitentan: The Hypertension Drug Once Rejected by J&J Now Secures FDA Approval for Market Release
Hot Spotlight
10 min read
Aprocitentan: The Hypertension Drug Once Rejected by J&J Now Secures FDA Approval for Market Release
26 March 2024
On March 20th, Idorsia, a Swiss pharma, announced FDA approval for their drug TRYVIO™ (aprocitentan) to be used alongside other antihypertensives for treating uncontrolled hypertension in adults.
Read →
Eli Lilly Reveals the Crystal Form Patent of FGFR3, Unveiling the Structure of LOXO-435
Hot Spotlight
6 min read
Eli Lilly Reveals the Crystal Form Patent of FGFR3, Unveiling the Structure of LOXO-435
21 March 2024
On March 14, 2024, Eli Lilly unveiled a WO patent for a crystalline salt form of an FGFR3 inhibitor, likely relating to LOXO-435's structure, within the pyrimido[4,5-b]pyrazine compound class.
Read →
Boehringer Ingelheim: Continuously Investing in the Development of Schizophrenia Treatment Drugs Targeting GPR52
Hot Spotlight
7 min read
Boehringer Ingelheim: Continuously Investing in the Development of Schizophrenia Treatment Drugs Targeting GPR52
19 March 2024
On March 11th, Boehringer Ingelheim partnered with Sosei Group in an exclusive deal to create and market a novel schizophrenia drug, a GPR52 agonist.
Read →
Several bispecific antibodies targeting GPCRs
Hot Spotlight
5 min read
Several bispecific antibodies targeting GPCRs
15 March 2024
Bispecific antibodies (bsAbs) possess unique advantages due to their ability to simultaneously target two distinct antigens, which helps to enhance the immune system's recognition and killing of tumor cells.
Read →
Tegileridine vs Oliceridine: Comparison of New Analgesic Drugs Targeting Opioid Receptors
Hot Spotlight
7 min read
Tegileridine vs Oliceridine: Comparison of New Analgesic Drugs Targeting Opioid Receptors
15 March 2024
In January, Jiangsu Hengrui Pharmaceuticals' Tegileridine Fumarate injection, for treating moderate to severe post-op abdominal pain, was approved in China.
Read →
Latest Advances and Applications of Bispecific Antibodies in Cancer Treatment
Hot Spotlight
15 min read
Latest Advances and Applications of Bispecific Antibodies in Cancer Treatment
12 March 2024
On March 6th, Nature Reviews Drug Discovery highlighted recent bispecific antibodies (bsAbs) progress in cancer therapy.
Read →
Progress on Amgen's Weight Loss Pipeline: AMG 133
Hot Spotlight
10 min read
Progress on Amgen's Weight Loss Pipeline: AMG 133
12 March 2024
In February, Amgen published a study in Nature Metabolism about AMG 133, a novel molecule with potential for treating obesity.
Read →
Tharimmune's Oral Mucosal Film Medication TH104 Targeting Opioid Receptors
Hot Spotlight
4 min read
Tharimmune's Oral Mucosal Film Medication TH104 Targeting Opioid Receptors
12 March 2024
Tharimmune revealed on their website plans to start a Phase 1 trial for TH104, assessing safety and bioavailability, with early results due Q2 2024.
Read →